The Sunshine Act is a federal transparency law that requires drug and medical device companies to publicly report any payments they make to doctors, teaching hospitals, and other healthcare providers. Officially called the Physician Payments Sunshine Act, it was enacted as part of the Affordable Care Act in 2010 and is administered by the Centers for Medicare and Medicaid Services (CMS). The data is published in a free, searchable database called Open Payments, where anyone can look up a specific provider and see what financial relationships they have with industry.
Why the Law Exists
Pharmaceutical and medical device companies routinely pay healthcare providers for legitimate activities: consulting, speaking at conferences, conducting research, and participating in advisory boards. But these financial ties can also create conflicts of interest. A doctor who receives significant payments from a drug manufacturer might, consciously or not, favor that company’s products when making treatment decisions.
The Sunshine Act doesn’t ban these relationships. It makes them visible. The core idea is that patients, researchers, and journalists can check whether a provider has financial ties to companies whose products they prescribe or recommend. CMS describes the program as “one of many steps in the Affordable Care Act designed to create greater transparency in the health care market.”
Who Has to Report
The reporting obligation falls on two types of entities. The first is “applicable manufacturers,” meaning companies that produce drugs, devices, biological products, or medical supplies covered by Medicare, Medicaid, or the Children’s Health Insurance Program (CHIP). This includes companies that make the products and related entities under common ownership that help with marketing, promotion, or distribution. It does not include pure distributors or wholesalers that never hold title to the product.
The second group is group purchasing organizations (GPOs), which negotiate or arrange purchases of covered products on behalf of groups of healthcare providers. GPOs must report any ownership or investment interests that physicians or their immediate family members hold in the organization.
Who Receives Reported Payments
The law originally applied only to physicians and teaching hospitals. The SUPPORT Act later expanded the definition of “covered recipients” to include advanced practice providers, a category that brings in nurse practitioners, physician assistants, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives. If you fall into any of these groups and a manufacturer buys you lunch, pays you a consulting fee, or covers your travel to a conference, that transaction is reportable.
What Gets Reported
Manufacturers must categorize each payment into one of 18 specific categories. These cover a broad range of financial interactions: consulting fees, compensation for speaking or serving on advisory boards, meals, travel and lodging, education, research grants, charitable contributions, royalties or licenses, entertainment, and gifts, among others. Dividends and other returns on investment are also reportable when a physician holds an ownership stake in a company.
Beyond direct payments, the law requires reporting of physician ownership and investment interests in manufacturing companies. Reports must include the dollar amount invested, the value and terms of the interest, and whether the stake is held by the physician directly or by an immediate family member. Any payments made to a physician who also holds an ownership interest get reported separately under the standard payment rules.
Reporting Thresholds
Not every dollar triggers a report. For the 2026 program year, individual payments below $13.82 are excluded. However, if the total value of all small payments to a single provider exceeds $138.13 in a calendar year, every payment must be reported, including the ones that fell below the per-transaction threshold. These thresholds are adjusted annually and tend to inch upward over time. In practice, the thresholds are low enough that even a few paid meals over the course of a year can cross the aggregate line.
How the Reporting Cycle Works
Manufacturers and GPOs collect data throughout the calendar year, from January 1 through December 31. The following year, they submit that data to CMS. Before the data goes public, covered recipients get a window to review, affirm, or dispute the information attributed to them. If a doctor believes a reported payment is inaccurate, they can flag it during this review period. CMS is required by law to publish the annual data by June 30 of the year after collection, making it available on the Open Payments website.
Penalties for Not Reporting
Companies that fail to report accurately, completely, or on time face civil monetary penalties of up to $1,000,000 per year (adjusted annually). CMS can audit reporting entities to verify compliance. The penalties apply to the manufacturers and GPOs, not to the healthcare providers who receive payments. Providers have no legal obligation to report under this law, though many professional organizations encourage them to review their Open Payments profiles for accuracy.
How to Use Open Payments
The Open Payments database is publicly accessible at openpaymentsdata.cms.gov. You can search by provider name, company name, or teaching hospital. Each result shows the type and dollar amount of every reported transaction. If your orthopedic surgeon received $50,000 in consulting fees from a joint implant manufacturer last year, that information is there.
Context matters when interpreting the data. A large research payment doesn’t necessarily mean a provider is biased. It could reflect legitimate scientific work. Similarly, a few reported meals at a medical conference are routine in the industry. The database is a starting point for understanding financial relationships, not a verdict on a provider’s integrity. But patterns can be telling: a provider who receives hundreds of thousands of dollars from a single company while heavily prescribing that company’s products is worth questioning.